From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Paris, France
Key people
Laurent Lévy
( CEO)
Number of employees
31 (2011)

Nanobiotix is a nanomedicine company dedicated to the development of new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.[1] The company is based in Paris.


Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 [2] and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE).

Corporate structure[edit]

  • Chief Executive Officer (CEO) and Chairman of the Board: Laurent Levy
  • Chief Financial Officer (CFO) and (COO): Kader Boussaha [3]


Nanobiotix has developed a new class of therapeutics based on nanoparticles, NanoXray™ therapeutics.[4][5] They consist of inert nanoparticles designed to enter tumor cells. They are injected via syringe directly into tumors.[6] Upon activation by a standard dose of radiation, they release free radicals that destroys cancer cells, whilst the surrounding healthy tissues are preserved and receive the same dose of radiation as in standard radiotherapy.[7]

Research and development[edit]

Nanobiotix has already won 10 public and private awards and owns 9 original umbrella patents. [8]



  1. ^ "Nanobiotix website".
  2. ^ "France Biotech".
  3. ^ "Corporate profile" (PDF). Archived from the original (PDF) on 2010-11-27.
  4. ^ "Biotech Finances".
  5. ^ "Nanobiotix Reports Exciting Preclinical Results Using Its NanoXray™ Therapeutics Technology To Destroy Tumors May 2009 Medical News Today".
  6. ^ "PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma". 8 October 2014.
  7. ^ "NanoXray video". nanobiotix.
  8. ^ "Company fact sheet" (PDF). Archived from the original (PDF) on 2010-11-27.
  9. ^ Nanobiotix gets FDA nod. Jan 2018
  10. ^ "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall".
  11. ^ "NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers".
  12. ^ "NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma".
  13. ^ "NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx".

External links[edit]